For Q1 FY2026 ended March 31, 2026, Boston Scientific reported revenue of $5.203 billion, up 11.6% year-over-year. Operating income was $1.101 billion, up 19.5% YoY, and net income was $190 million, up 302.1% YoY. Diluted EPS was $0.90, doubling from the prior year. Cash and cash equivalents stood at $1.453 billion, with total equity of $25.864 billion.
•Revenue grew 11.6% YoY to $5.203 billion.
•Operating income increased 19.5% YoY to $1.101 billion.
•Net income surged 302.1% YoY to $190 million.
•Diluted EPS doubled to $0.90.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. The company operates in two segments, MedSurg and Cardiovascular.
It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes Endoluminal surgery and infection prevention products. Its portfolio also includes devices to treat urological conditions
Including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems, and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems, as well as technologies for diagnosing and treating a range of diseases and abnormalities of the heart.
Its portfolio also includes WATCHMAN FLX, a left atrial appendage closure (LAAC) device, and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems.
Additionally, it offers diagnosis and treatment of rate and rhythm disorders of the heart. Its portfolio also includes peripheral arterial and venous diseases, and products to diagnose and treat forms of cancer. Incorporated in 1979, the company is headquartered in Marlborough, Massachusetts.
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. The company operates through two segments: MedSurg and Cardiovascular. Its MedSurg segment offers devices for gastrointestinal conditions, such as resolution clips, biliary stent systems, and single-use scopes like SpyGlass for pancreaticobiliary procedures. It also provides urological devices including ureteral stents, catheters, and holmium laser systems, as well as neurological products like spinal cord stimulators and deep brain stimulation systems for chronic pain and movement disorders. The Cardiovascular segment includes products for diagnosing and treating heart diseases, such as the WATCHMAN FLX left atrial appendage closure device, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices.
Where is Boston Scientific Corporation (BSX) listed and what currency does it trade in?
Boston Scientific Corporation is listed on the New York Stock Exchange (NYSE) under the ticker symbol BSX. The company trades in United States Dollars (USD), as it is headquartered in the United States. Being listed on the NYSE, one of the world's largest stock exchanges, provides liquidity and visibility to global investors. The stock is part of the Healthcare sector, specifically the Medical Devices industry, and is widely followed by investors interested in the medical technology space.
What sector and industry does Boston Scientific Corporation (BSX) belong to?
Boston Scientific Corporation operates in the Healthcare sector and is classified under the Medical Devices industry. This means the company focuses on developing and manufacturing medical equipment and technologies used by healthcare professionals to diagnose, treat, and manage various medical conditions. As a medical device company, Boston Scientific's products range from minimally invasive surgical tools to implantable devices for cardiac, neurological, and urological applications. The industry is highly regulated and innovation-driven, with companies like Boston Scientific competing on technological advancements, clinical outcomes, and global market reach.
Where is Boston Scientific Corporation (BSX) headquartered and what markets does it serve?
Boston Scientific Corporation is headquartered in the United States and serves markets globally. The company's products are used in interventional medical specialties around the world, including gastrointestinal, urological, neurological, and cardiovascular procedures. With a presence in many countries, Boston Scientific distributes its medical devices to hospitals, clinics, and healthcare providers across different regions. The company's global reach allows it to address diverse healthcare needs, from developed markets like the US and Europe to emerging markets. Its international operations are supported by manufacturing and research facilities, though specific locations are not detailed in the provided data.
How does Boston Scientific Corporation (BSX) generate revenue?
Boston Scientific Corporation generates revenue by developing, manufacturing, and selling medical devices across two main segments: MedSurg and Cardiovascular. The MedSurg segment includes products for gastrointestinal, urological, and neurological procedures, such as endoscopic devices, ureteral stents, and spinal cord stimulators. The Cardiovascular segment offers devices for heart rhythm management, coronary interventions, and structural heart conditions, including defibrillators, pacemakers, and the WATCHMAN FLX left atrial appendage closure device. Revenue comes from direct sales to healthcare providers, as well as through distributors. The company's diverse portfolio allows it to capture value across multiple high-growth medical specialties, with a focus on minimally invasive technologies that improve patient outcomes.